New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
06:49 EDTCELG, MYLMylan sues Celgene for blocking Thalomid, Revlimid generics, Reuters says
Mylan (MYL) sued Celgene (CELG) to stop the latter's effort to keep generic versions of Revlimid and Thalomid off the market, according to Reuters, citing comments from Mylan. Combined, both drugs generate $4.5B of annual sales. Reference Link
News For MYL;CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 28, 2015
09:31 EDTMYLMylan vote not surprising, Perrigo likely to rise in near-term, says BMO Capital
BMO Capital analyst David Maris believes that Mylan (MYL) shareholders' vote in favor of Mylan's proposed takeover of Perrigo (PRGO) and authorizing the company to issue shares was the outcome expected by most investors and will not come as a surprise to the market. Maris noted that he expects Perrigo shares will rise in the coming days amid speculation on its next move and thinks the Mylan bid significantly undervalues the company, which he estimates is worth $246 per share on a stand-alone basis. The firm keeps an Outperform rating on Perrigo and a Market Perform rating on Mylan.
08:06 EDTMYLPerrigo 'confident' shareholders will reject Mylan 's offer
Subscribe for More Information
07:22 EDTMYLMylan shareholders approve proposed acquisition of Perrigo
Subscribe for More Information
07:12 EDTCELGWilliam Blair names 21 stocks best positioned for volatile markets
Subscribe for More Information
August 27, 2015
16:03 EDTCELGCelgene completes acquisition of Receptos
Subscribe for More Information
August 26, 2015
10:07 EDTMYLMylan initiated with a Buy at Standpoint Research
Subscribe for More Information
06:55 EDTMYLMylan shares may sell off on affirmative Perrigo deal vote, says BMO Capital
With Mylan (MYL) set to hold a shareholder vote on August 28 regarding its proposed acquisition of Perrigo (PRGO), BMO Capital analyst David Maris predicts that if the vote goes in Mylan's favor, he expects Perrigo shares to rise and Mylan shares to fall. Afterward, he feels added overhangs, such as Teva's (TEVA) and Abbott's (ABT) shareholdings and potential short-term selling by arbitrageurs, will come into play, further pressuring Mylan shares.
05:58 EDTMYLPerrigo CEO says company is 'very active in M&A,' Bloomberg reports
Subscribe for More Information
August 25, 2015
15:02 EDTMYLMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTMYLTeva Copaxone patents to be reconsidered by regulators, Bloomberg says
14:16 EDTMYLMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
13:22 EDTMYLMylan comments on 'misleading' Perrigo statements
Subscribe for More Information
11:27 EDTMYLTeva to refrain from voting at Mylan special meeting
Subscribe for More Information
07:31 EDTCELGCelgene announces expiration of tender offer for Receptos shares
Subscribe for More Information
August 24, 2015
18:55 EDTCELGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTCELGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
13:36 EDTCELGBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
August 23, 2015
12:35 EDTCELGBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
15:22 EDTMYLMylan clarifies certain inaccuracies related to lowered condition to acquire Perrigo
Subscribe for More Information
08:19 EDTMYLMylan to host special shareholder meeting
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use